Overview

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and the safety of concomitant use of Ezetimibe/Rosuvastatin combination tablets and Candesartan cilexetil/Amlodipine besylate combination tablets compared to each combination tablet alone in patients with essential hypertension (HTN) and hyperlipidemia.

Phase:

Phase 4

Details

Lead Sponsor:

CJ HealthCare Corporation
HK inno.N Corporation

Treatments:

Amlodipine
Candesartan
Candesartan cilexetil
Ezetimibe
Rosuvastatin Calcium